SALANI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 505
EU - Europa 415
AS - Asia 89
AF - Africa 79
Totale 1.088
Nazione #
US - Stati Uniti d'America 505
IT - Italia 174
SE - Svezia 130
SG - Singapore 54
CI - Costa d'Avorio 51
BG - Bulgaria 35
AT - Austria 27
GB - Regno Unito 23
NG - Nigeria 18
CN - Cina 14
SN - Senegal 10
DE - Germania 8
PL - Polonia 8
HK - Hong Kong 7
VN - Vietnam 6
IN - India 3
IR - Iran 3
BE - Belgio 2
CH - Svizzera 2
FR - Francia 2
RO - Romania 2
FI - Finlandia 1
JP - Giappone 1
LK - Sri Lanka 1
UA - Ucraina 1
Totale 1.088
Città #
Chandler 90
Fairfield 54
Abidjan 51
New York 42
Milan 36
Ashburn 35
Sofia 35
Seattle 30
Florence 27
Vienna 27
Pisa 20
Woodbridge 20
Lagos 18
London 18
Lawrence 17
Princeton 17
Cambridge 16
Wilmington 15
Kent 12
Dakar 10
Medford 10
Houston 9
Ann Arbor 7
Beijing 7
Hong Kong 7
Warsaw 7
Los Angeles 6
Norwalk 5
Rome 5
Vicopisano 5
Castiglione Chiavarese 4
Frankfurt am Main 4
Piombino 4
San Diego 4
Singapore 4
Bremen 3
Center 3
Massa 3
Santa Croce sull'Arno 3
Shanghai 3
Turin 3
Bologna 2
Brussels 2
Ebikon 2
Farra di Soligo 2
Forlì 2
Lucca 2
Messina 2
Ogden 2
Romainville 2
Serra 2
Sesto San Giovanni 2
Barletta 1
Carugate 1
Casaleone 1
Changsha 1
Ciampino 1
Formigine 1
Fulham 1
Garbagnate Milanese 1
Hangzhou 1
Islington 1
Kashan 1
Lappeenranta 1
Livorno 1
Minerbio 1
Minneapolis 1
New Delhi 1
North Charleston 1
Pietrasanta 1
Redmond 1
Redwood City 1
Rosignano Marittimo 1
Southwark 1
Stuttgart 1
Venezia 1
Viareggio 1
Vicenza 1
Washington 1
Yokohama 1
Totale 746
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 108
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 88
Invasive Meningococcal Disease due to group C N. meningitidis ST11 (cc11): The Tuscany cluster 2015–2016 76
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 71
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 66
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 64
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients 59
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 57
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis 50
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 43
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 42
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma 39
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 38
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 38
Combination chemotherapy in patients with advanced pancreatic cancer with an eastern cooperative oncology group performance status of 2: Lights and shadows of a frail route 38
In Reply 38
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study 28
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib 27
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 26
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 21
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 20
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice 18
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies 17
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 16
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy 14
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 12
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 9
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer 9
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 9
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer 8
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 4
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 4
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 2
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 2
Totale 1.161
Categoria #
all - tutte 5.166
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.166


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202076 3 9 0 4 4 5 9 9 8 5 17 3
2020/202192 6 2 4 5 6 20 3 5 11 8 10 12
2021/2022193 0 1 3 6 40 40 4 2 17 12 22 46
2022/2023452 47 69 33 15 50 58 6 35 91 2 37 9
2023/2024348 21 40 41 25 58 38 64 16 5 17 23 0
Totale 1.161